Jacobs Levy Equity Management Inc. Has $3.78 Million Stake in DaVita Inc. (NYSE:DVA)

Jacobs Levy Equity Management Inc. decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 35.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,253 shares of the company's stock after selling 14,165 shares during the quarter. Jacobs Levy Equity Management Inc.'s holdings in DaVita were worth $3,777,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in shares of DaVita in the 4th quarter valued at $41,000. Coppell Advisory Solutions LLC increased its position in shares of DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after buying an additional 100 shares in the last quarter. Canada Post Corp Registered Pension Plan bought a new stake in shares of DaVita in the 4th quarter valued at $55,000. Venturi Wealth Management LLC increased its holdings in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after purchasing an additional 152 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in DaVita by 39.7% during the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after purchasing an additional 131 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Up 1.5%

Shares of DaVita stock traded up $2.20 during trading hours on Tuesday, reaching $147.16. 193,176 shares of the company's stock were exchanged, compared to its average volume of 828,426. The company has a 50 day moving average of $145.72 and a two-hundred day moving average of $153.60. DaVita Inc. has a fifty-two week low of $131.44 and a fifty-two week high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock has a market cap of $11.11 billion, a P/E ratio of 13.72, a P/E/G ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The business had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period last year, the business posted $2.26 EPS. DaVita's revenue was up 5.0% on a year-over-year basis. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Truist Financial reduced their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, DaVita has a consensus rating of "Hold" and a consensus target price of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.